Cancer Treatment Breakthrough: Hoth Therapeutics Shows Promise

Hoth Therapeutics has shared some exciting news from their ongoing cancer trial. The company is testing a treatment called HT-001 on patients who are also taking EGFR inhibitor therapy. The results so far are quite impressive. In the trial, every patient who could be evaluated showed a positive response by the sixth week. That's a 100% success rate! Not only that, but the severity of their disease was cut by about half. This is a big deal because it shows the treatment is effective and works quickly. The improvements were seen as early as three weeks and lasted through the sixth week. This means the treatment not only starts working fast but also keeps working. On top of that, there were other benefits. For example, there was a 34% improvement in side effects from cancer treatment and a 37% reduction in itching, which is a common problem for these patients.Hoth Therapeutics is also working on other treatments. In a separate study, they found that their treatment HT-KIT caused significant tumor cell death in certain types of cancer. This is promising news for the future. Now, let's talk about the stock. Hoth Therapeutics' stock has been having a tough time lately. It's down about 22. 79% over the past year and is closer to its lowest point than its highest. However, there are some signs of hope. The stock is showing bullish momentum in the short term, which means it might be on the way up. Analysts seem to think the stock has potential. They've given it a "Buy" rating with an average price target of $6. 50. This is higher than the current stock price, so they believe it has room to grow.